line calcimimet
beat calcimimet guidanc rais
ticker report adj ep consensu
dialysi revenu consensu adj oper incom adj oi
consensu note adj oi aid calcimimet
manag acknowledg without boost quarter roughli line
intern expect note also elev cost relat ltip
result calcimimet larg beat increas adj oi guidanc
midpoint includ benefit calcimimet
expect continu tighten rang note adjust
calcimimet impli growth y/i
use number gave investor day also rais
adj ep guidanc lower previous expect share count
partial off-set impact ballot initi spend
rais est beat better outlook well rais po
new ebitda ebitda prior est
reiter buy rate dva solid long term outlook combin abil
deploy signific amount capit
beat rais adj oi guidanc midpoint
rais op cash flow guidanc midpoint meanwhil
lower capital-expenditure outlook midpoint although
delay rais adj ep guidanc
benefit lower share count partial off-set
headwind expect cost lobbi ballot initi ca also
note ballot initi worst everi year impli
tailwind ballot initi cost
non-acquir treatment growth vs
indic earli call floor encourag
lead indic volum growth
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
davita inc lead dialysi provid
unit state compani oper
outpati clinic us serv
patient also oper countri
outsid us
sale dmg improv balanc sheet
open signific capit deploy
meanwhil move home dialysi larg
posit better posit investor
realiz although headwind
look like year reacceler growth given
potenti growth medicar advantag
po base ebitda estim around midpoint
stand-alon histor rang ebitda dmg sale allow
focu core dialysi busi deploy capit
upsid risk po commerci mix better expect
reimburs better expect make chang third
downsid risk po commerci price pressur could continu
potenti commerci mix pressur manag care vast major dialysi
kevin fischbeck cfa herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us facil hospit manag healthcar coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
